Decernotinib (VX-509)

CAS : 944842-54-0

Ref. 3D-UMB84254

Informations sur le produit

• Nom: Decernotinib (VX-509)
• Synonymes: (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)butanamide, (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide, Adelatinib, Butanamide, 2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)-, (2R)-, V 509, Vrt 831509, Vx-509, Decernotinib(VX-509), (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide, Decernotinib

Description

Decernotinib is a small molecule inhibitor that binds to the ATP site of the polymerase chain reaction (PCR) enzyme. Decernotinib has shown efficacy in animal models of autoimmune diseases, such as alopecia areata and rheumatoid arthritis. It has also been shown to inhibit the response of primary cells isolated from patients with systemic lupus erythematosus and myasthenia gravis. The drug is expected to be used as an antirheumatic drug for the treatment of inflammatory diseases. Decernotinib has not yet been tested in humans, but it is predicted that this drug will have few side effects and no significant interactions with other drugs.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 392.38 g/mol
• Formule: C₁₈H₁₉F₃N₆O
• Degré de pureté: Min. 95%